ArticleKidney diseases (Basel, Switzerland)

Cardiovascular and Renal Outcomes with Ertugliflozin by Baseline Use of Renin-Angiotensin-Aldosterone System Inhibitors or Diuretics, Including Mineralocorticoid Receptor Antagonist: Analyses from the VERTIS CV Trial.

David Z I Cherney et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.